New shot aims to slash hepatitis b virus levels
NCT ID NCT05961098
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested an experimental injection called RBD1016 in 48 adults with chronic hepatitis B who were already taking standard antiviral pills. The goal was to see if the injection could safely lower hepatitis B surface antigen (HBsAg), a marker of the virus. Participants received either RBD1016 or a placebo, and researchers tracked side effects and changes in HBsAg levels over time.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Trial Consultants AB
Uppsala, Uppsala County, 752 37, Sweden
-
Karolinska University Hospital
Stockholm, Stockholm County, 141 86, Sweden
-
Prince of Wales Hospital
Hong Kong, China
-
Queen Mary Hospital
Hong Kong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new shot help control hepatitis d in people with hepatitis b?
- Stick-On ultrasound patch could spot liver damage without a specialist
- New drug combo aims to silence hepatitis b virus
- New DNA test could sharpen hepatitis b monitoring
- 10-Year hepatitis study aims to unlock secrets of liver disease
- Could a short course of antiviral drugs stop hepatitis b passing from mother to child?